Cargando…

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients

BACKGROUND AND AIM: The BNT162b2 COVID‐19 vaccine (Pfizer/BioNTech), given as a two‐dose series, 3 weeks apart, elicits a serological response in 84–98% of patients with cancer, even if administered while undergoing anticancer treatments. Herein, we report the impact of a third (booster) dose of BNT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shmueli, Einat Shacham, Lawrence, Yaacov R., Rahav, Galia, Itay, Amit, Lustig, Yaniv, Halpern, Naama, Boursi, Ben, Margalit, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347981/ https://www.ncbi.nlm.nih.gov/pubmed/35652556 http://dx.doi.org/10.1002/cnr2.1645

Ejemplares similares

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
por: Shacham-Shmueli, Einat, et al.
Publicado: (2022)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
por: Margalit, Ofer, et al.
Publicado: (2020)

Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer
por: Halpern, Naama, et al.
Publicado: (2023)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review
por: Halpern, Naama, et al.
Publicado: (2020)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Remitting seronegative symmetrical synovitis with pitting oedema following BNT162b2 mRNA COVID-19 vaccination
por: Parperis, Konstantinos, et al.
Publicado: (2021)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel
por: Guedalia, Joshua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7qkd42evqggsl00c58asqf13ea